CYMBALTA

LOE Approaching

duloxetine hydrochloride

Eli Lilly and Company
NDAORALCAPSULE, DELAYED REL PELLETS
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9

Mechanism of Action

antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.

Indications (4)

the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adultsolder () Chronic musculoskeletal pain in adults ()anxiety

Clinical Trials (5)

NCT03794154Phase 4Withdrawn

A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions

Started Mar 2020
0
Healthy
NCT03729284Phase 4Withdrawn

A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta

Started Mar 2020
0
Healthy
NCT01074151N/ACompleted

The Cymbalta Pregnancy Registry

Started Jul 2009
144 enrolled
Pregnancy
NCT00658931Phase 4Unknown

Cymbalta for Depression as a Complication of Bereavement

Started Apr 2008
20 enrolled
DepressionBereavement
NCT02215798N/ACompleted

Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients

Started Jul 2006
269 enrolled
Pain
Company
Eli Lilly and Company
Eli Lilly and Company
INDIANAPOLIS, IN
838 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers